Your browser doesn't support javascript.
loading
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.
Khoury, Joseph D; Solary, Eric; Abla, Oussama; Akkari, Yassmine; Alaggio, Rita; Apperley, Jane F; Bejar, Rafael; Berti, Emilio; Busque, Lambert; Chan, John K C; Chen, Weina; Chen, Xueyan; Chng, Wee-Joo; Choi, John K; Colmenero, Isabel; Coupland, Sarah E; Cross, Nicholas C P; De Jong, Daphne; Elghetany, M Tarek; Takahashi, Emiko; Emile, Jean-Francois; Ferry, Judith; Fogelstrand, Linda; Fontenay, Michaela; Germing, Ulrich; Gujral, Sumeet; Haferlach, Torsten; Harrison, Claire; Hodge, Jennelle C; Hu, Shimin; Jansen, Joop H; Kanagal-Shamanna, Rashmi; Kantarjian, Hagop M; Kratz, Christian P; Li, Xiao-Qiu; Lim, Megan S; Loeb, Keith; Loghavi, Sanam; Marcogliese, Andrea; Meshinchi, Soheil; Michaels, Phillip; Naresh, Kikkeri N; Natkunam, Yasodha; Nejati, Reza; Ott, German; Padron, Eric; Patel, Keyur P; Patkar, Nikhil; Picarsic, Jennifer; Platzbecker, Uwe.
Affiliation
  • Khoury JD; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jkhoury@unmc.edu.
  • Solary E; Department of Hematology, Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France. eric.solary@gustaveroussy.fr.
  • Abla O; Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada.
  • Akkari Y; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, USA.
  • Alaggio R; Pathology Unit, Department of Laboratories, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy.
  • Apperley JF; Centre for Haematology, Imperial College London, London, UK.
  • Bejar R; Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
  • Berti E; University of Milan, Fondazione Cà Granda, IRCCS, Ospedale Maggiore Policlinico, Milano, Italy.
  • Busque L; Service d'hématologie, oncologie et transplantation, Hôpital Maisonneuve-Rosemont, Université de Montréal, Montréal, QC, Canada.
  • Chan JKC; Department of Pathology, Queen Elizabeth Hospital, Kowloon, Hong Kong.
  • Chen W; Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Chen X; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
  • Chng WJ; Department of Hematology-Oncology, National University Cancer Institute, Singapore, Singapore.
  • Choi JK; Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, USA.
  • Colmenero I; Department of Pathology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain.
  • Coupland SE; Liverpool Clinical Laboratories, Liverpool University Hospitals Foundation Trust, Liverpool, UK.
  • Cross NCP; Faculty of Medicine, University of Southampton, Southampton, UK.
  • De Jong D; Amsterdam UMC, Location Vrije Universiteit Amsterdam, Department of Pathology, Amsterdam, The Netherlands.
  • Elghetany MT; Department of Pathology & Immunology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA.
  • Takahashi E; Department of Pathology, Aichi Medical University Hospital, Nagakute, Japan.
  • Emile JF; Department of Pathology, Ambroise Pare Hospital, AP-HP and Versailles SQY University, Boulogne, France.
  • Ferry J; Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Fogelstrand L; Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg and Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Fontenay M; Laboratory of Hematology, Assistance Publique-Hôpitaux de Paris, Cochin Hospital and Université Paris Cité, CNRS, INSERM, Cochin Institute, Paris, France.
  • Germing U; Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany.
  • Gujral S; Department of Pathology, Tata Memorial Hospital, Mumbai, India.
  • Haferlach T; MLL Munich Leukemia Laboratory, Munich, Germany.
  • Harrison C; Department of Haematology, Guys and St Thomas' NHS Foundation Trust, London, UK.
  • Hodge JC; Indiana University School of Medicine, Indianapolis, IN, USA.
  • Hu S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jansen JH; Lab Hematology, Dept LABGK, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Kanagal-Shamanna R; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kratz CP; Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
  • Li XQ; Departments of Pathology and Oncology, Fudan University, Shanghai, China.
  • Lim MS; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Loeb K; Section of Pathology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Marcogliese A; Department of Pathology & Immunology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA.
  • Meshinchi S; Pediatric Hematology and Oncology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Michaels P; Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Naresh KN; Section of Pathology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Natkunam Y; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
  • Nejati R; Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA, USA.
  • Ott G; Department of Clinical Pathology, Robert-Bosch-Krankenhaus, and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
  • Padron E; Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Patel KP; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Patkar N; Hematopathology Laboratory, Tata Memorial Hospital, Mumbai, India.
  • Picarsic J; Pathology and Lab Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
  • Platzbecker U; Department of Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany.
Leukemia ; 36(7): 1703-1719, 2022 07.
Article in En | MEDLINE | ID: mdl-35732831
ABSTRACT
The upcoming 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours is part of an effort to hierarchically catalogue human cancers arising in various organ systems within a single relational database. This paper summarizes the new WHO classification scheme for myeloid and histiocytic/dendritic neoplasms and provides an overview of the principles and rationale underpinning changes from the prior edition. The definition and diagnosis of disease types continues to be based on multiple clinicopathologic parameters, but with refinement of diagnostic criteria and emphasis on therapeutically and/or prognostically actionable biomarkers. While a genetic basis for defining diseases is sought where possible, the classification strives to keep practical worldwide applicability in perspective. The result is an enhanced, contemporary, evidence-based classification of myeloid and histiocytic/dendritic neoplasms, rooted in molecular biology and an organizational structure that permits future scalability as new discoveries continue to inexorably inform future editions.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 2_ODS3 Database: MEDLINE Main subject: Histiocytosis / Hematologic Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Leukemia Year: 2022 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 2_ODS3 Database: MEDLINE Main subject: Histiocytosis / Hematologic Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Leukemia Year: 2022 Document type: Article